10 results
424B3
SYRS
Syros Pharmaceuticals Inc.
8 Aug 22
Prospectus supplement
5:47pm
strategic alternatives available to Tyme, including a liquidation of Tyme and the distribution of any available cash after wind down;
Tyme’s board … the pendency of the merger;
the substantial expenses to be incurred by Syros in connection with the merger;
wind-down costs and resource requirements
S-4
SYRS
Syros Pharmaceuticals Inc.
18 Jul 22
Registration of securities issued in business combination transactions
7:58am
wind down;
Tyme’s board of directors’ belief that, as a result of arm’s length negotiations with Syros, Tyme and its representatives negotiated … in connection with the merger;
wind-down costs and resource requirements associated with Tyme’s operations and administration, including those associated
8-K
EX-99.1
SYRS
Syros Pharmaceuticals Inc.
5 Jul 22
Syros to Raise Approximately $190 Million Through Merger with TYME Technologies and Concurrent Private Placement
7:07am
agreement pursuant to which Syros will acquire TYME, including its pipeline assets and net cash at closing which after accounting for wind-down
8-K
ljmis 8d4
8 Mar 22
Entry into a Material Definitive Agreement
7:01am
- Prev
- 1
- Next